西罗莫司洗脱支架(Cypher^(TM))治疗支架内再狭窄  

Sirolimus-eluting stents for the treatment of in-stent restonosis

作　　者：李忠红[1] 衣为民[1] 彭长农[1] 龙娟[1] 王丽丽[1] 

机构地区：[1]深圳市孙逸仙心血管医院心内科,心血管研究所518021

出　　处：《中国介入心脏病学杂志》2005年第5期299-300,共2页Chinese Journal of Interventional Cardiology

摘　　要：目的探讨CypherTM药物洗脱支架治疗支架内再狭窄的安全性和有效性。方法11例支架内再狭窄患者共置入CypherTM药物洗脱支架15枚,所有患者随访6个月,并于术后6个月复查冠状动脉造影。结果介入手术成功率100%,未发生与介入治疗相关的并发症。术后所有患者临床症状明显改善,6个月复查冠状动脉造影,无一例发生再狭窄。结论西罗莫司(雷帕霉素)洗脱支架治疗支架内再狭窄有很强的安全性、有效性。Objective To evalute the feasibility and safety of sirolimus （rapamyein）-eluting stent for the treatment of in-stent restenosis （ISR）. Methods Eleven patients with 1SR were treated with one or more Cypher^TM sirolimus-eluting stents. All these patients received angiographic follow-up at 6 months. Results The success rate of the procedure was 100% . All patients were free of angina after 6 months. There were no repeat revascularizations, stent thrombosis or major adverse clinical events during the follow up period. No ISR was noted in the follow-up coronary angiography. Conclusion This study demonstrates the safety and potential of sirolimus-eluting stents for the treatment of ISR.

关 键 词：支架 再狭窄 西罗莫司 支架内再狭窄 药物洗脱支架 支架治疗 西罗莫司 冠状动脉造影 介入手术 临床症状 治疗相关 雷帕霉素 

分 类 号：R654.2[医药卫生—外科学] R541.4[医药卫生—临床医学]